The results favor the hypothesis that dopamine deficiency in PD not only relate to mild cognitive deficits in frontostriatal functions, but also to a decline in memory and attention. This could indicate that dopamine deficiency impairs a wide network of brain areas.
Catechol-O-methyltransferase (COMT) gene polymorphism (Val 158
Val homozygotes, 7 and higher prefrontal dopamine activation as measured by PET. 8 The COMT
158
Val-allele correlates with lower scores in tests of working memory in healthy volunteers (showing complex relations to the same functions in PD), and with gray matter atrophy in dopamine-innervated brain areas in patients with dementia disorders. 9 Also affecting dopamine transmission, the C 957 T polymorphism of the Dopamine Receptor D2 (DRD2) gene (rs6277) affects messenger RNA stability, 10 thereby influencing the level of expression of D2 receptors in the brain. The 957 C/C genotype correlates with higher D2
receptor densities in extrastriatal, thalamic and neocortical areas, 11 and better episodic memory in healthy elders. 12 Hypofunction of extrastriatal dopamine receptor D2 subsystems, including in the insula, was recently found to contribute to cognitive decline in PD. 13, 14 Variability in genes related to dopamine transmission can potentially clarify the role of dopamine deficiency in relation to cognitive decline in PD. Therefore, we investigated the above-mentioned polymorphisms and cognitive functions in prospectively followed patients with PD. As a measurement of structural integrity, we included a sensitive CSF biomarker for neurodegeneration of myelinated axons (neurofilament light chain; NFL). 15 
| MATERIALS AND METHODS

| Participants
All patients with PD participated in a prospective, populationbased incidence study of unselected cases of new-onset idiopathic parkinsonism, from a geographically defined area in Sweden.
The study design has been described previously in detail. 16 In brief, inclusion lasted from January 1, 2004 
| Cognitive impairment
Extensive neuropsychological testing, covering specific cognitive domains and used for PD-mild cognitive impairment (MCI) and PD dementia (PDD) diagnostics, was performed at 0, 1, 3, 5, and 8 years.
18
MCI was diagnosed according to Movement Disorder Society criteria. 19 As the protocol included two tests of all cognitive domains but language, MCI was diagnosed on modified level 2 criteria, in keeping with previous research. 20 See Table 1 Table 1 ). 19 The domain scores (measured by average standard deviations above or below the score mean at baseline; ie, Z-score) in five domains, throughout the study period, and CSF NFL concentrations (tested at 0, 1, and 3 years), were compared in the genotype groups by linear mixed models, run with and without adjustment (see Table 4 ). The use of mixed-effects models accounts for variability in length of follow-up and is flexible with missing data. Although used in MCI diagnostics, language was excluded from mixed model , and executive function e . Subjects were classified as having mild cognitive impairment (PD-MCI) if: (i) impaired in a minimum of two tests in one domain (single domain MCI) or in a minimumofonetestintwodifferentdomains(multipledomainMCI),(ii)impairmentswere≥1.5standarddeviationsbelowmeanofnormativedata,(iii) self-perceived cognitive decline was reported by Questionnaire and/or directly by patient and/or family member, and (iv) no functional impairment in basic activities of living. Parkinson's disease dementia (PDD) diagnoses were based on neuropsychological test results, objective and subjective cognitive decline, and by the occurrence of functional impairment in basic activities of living (ie, driving a car, social or personal care, medication management) due to cognitive decline.
T A B L E 1 Tests used for Parkinson's disease cognitive impairment classification
Neuropsychological function Test
analyses because of non-normal distribution of scores. Differences in episodic memory (if found) were further analyzed in free-and cued recall conditions. P < .05 was considered significant. HolmBonferroni correction for multiple comparisons was made in the Cox regression models and the mixed model analyses (see Tables 3 and   4 ). All statistical analyses were performed using a software program (SPSS 23.0; SPSS Inc). 
| RESULTS
COMT
| COMT genotype in PD
As shown in Figure 2A , the COMT 158 Val/Val genotype increased the risk of any cognitive decline in PD during follow-up (decline from PDnormal to PD-MCI or from PD-MCI to PDD, P = .006). However, as shown by Cox regression (Table 3 ) and in Figure 2B , the increased risk of cognitive decline was driven by a higher incidence of PD-MCI 
| DRD2 genotype in PD
As shown in Figure 2D , the DRD2
957
T/T genotype increased the risk of any cognitive decline in PD, measured by incidence of either PD-MCI T/T genotype was also a risk factor for PD-MCI development among patients with normal cognition at baseline (n = 80, P = .018, Table 3 ).
Conversely, carriers of any DRD2
957
C alleles had a lower risk of all types of cognitive decline ( Figure 2FD -; Table 3 ). Analysis of test scores in specific cognitive domains showed that carriers of the DRD2 957 T/T genotype had significantly poorer performances in episodic memory (on average 0.25 standard deviations lower scores, P = .007) and in attention (on average 0.58 standard deviations lower scores, P < .001) after correction for confounding factors ( T/T genotype had a significantly poorer performance in free recall (P = .021), they performed better in cued recall (P = .026).
NFL concentrations in CSF did not differ between the DRD2 genotypes.
In the group of healthy control participants, DRD2
T/T carriers performed poorer in tests of attention at an uncorrected statistical threshold (on average 0.47 standard deviations lower scores, P = .031, after correction for age, sex, time of testing, and years of education), similar to the performance in patients with PD. The difference was, however, non-significant corrected for multiple comparisons.
| DISCUSSION
By prospectively following a population-representative cohort of patients with PD with neuropsychological evaluations for up to 10 years, we found that two common, functional polymorphisms in genes related to dopamine transmission (the COMT and DRD2 genes), affect the evolution of cognitive deficits, and alter the risks of MCI and PDD. According to the "dual syndrome hypothesis," the early, dopamine dysfunction-related impairments of frontostriatal, executive functions in PD are stable and do not strongly relate to dementia, while the more "posterior" deficits in visuospatial function or memory relate to cortical pathology that is predictive of PDD. 25 The present findings potentially modify this hypothesis. In particular, the finding of DRD2 In healthy subjects, the high-activity COMT 158 Val-allele has generally been found to impair executive functions such as working memory and cognitive flexibility. 26, 27 In PD, studies by Williams-Gray et al. showed that in later disease phases (>1.6 years after diagnosis), the Val-allele correlated with impairments in executive functioning (as measured by the "Tower of London" test), similar to findings in controls, while in early disease (<1.6 years after diagnosis), the effect was opposite. 4, 28 This was suggested to result from an inverted In relation to DRD2 function, patients with PD often experience memory problems characterized by an inability to recall information.
This may partly relate to dopamine deficiency. The hippocampus is strongly interconnected with dopaminergic neurons in the midbrain, 29 and several lines of evidence have established the importance of D2 receptor function in attention and memory. 30 Specifically, the DRD2 system is linked to transient memory updating processes. 31, 32 A reduction in D2 receptors has been found in PD 13 and in imaging studies, memory deficits in PD are correlated with reduced extrastriatal D2 receptor binding in the medial temporal lobe, including the insula, in parts of the so-called salience network. 14 Interestingly, the DRD2 957 C/C genotype (and the DRD2 gene locus) has previously been found to be associated to susceptibility to schizophrenia in younger populations. 33, 34 The seemingly opposite effects of the DRD2 957 C allele in different populations (increasing the risk of schizophrenia in young populations, while protecting against cognitive decline in PD) may be an example of genetic pleiotropism.
The precise mechanisms behind the DRD2-genotype-induced effects on cognition were not determined by this study but merits further investigation.
While the effects on cognition were different for the COMT and DRD2 genotypes, none of the genotypes affected cerebrospinal fluid NFL concentration (which has been found predictive of PDD). 35 This suggests that the COMT and DRD2 genotypes did not affect cognition through gross effects on neurodegeneration, at least not as measured by injury of myelinated axons. This is consistent with the trend of a similarly poorer performance in tests of attention in the healthy control persons with a DRD2 957 T/T genotype, which may indicate that the DRD2 genotype-related effect on attention is not specific to degenerating dopaminergic systems, but rather is an effect on functions common to both disease-affected and normal brains. The effect may, however, be amplified in PD. It could also be of interest to investigate the studied genotypes in Lewy Body Dementia.
A limitation was the small number of healthy controls and patients and the theoretical classification of cognitive tests in cognitive domains, which is, however, not standardized in clinical research settings. Our study also has strengths, namely a population-based and longitudinal design, evaluation of incident cases, and the use of an extensive neuropsychological test battery at several times during the follow-up period. The risk of incorrect PD diagnosis was minimized by the long follow-up periods, the finding of pathologic uptake on DATscan examination in all (100%) of the examined patients with PD, and by confirmation of the diagnosis by autopsy in a small number of cases.
In conclusion, although confirmation in independent, larger studies is needed, our results suggest that the COMT 
